REDWOOD CITY, Calif.,
July 5, 2017 /PRNewswire/
-- Nevro Corp. (NYSE: NVRO), a global medical device company
that is providing innovative evidence-based solutions for the
treatment of chronic pain, today announced its preliminary
unaudited revenue for the second quarter ended June 30, 2017.
The company announced that preliminary unaudited second quarter
worldwide revenue is expected to be in the range of $77.5 to $78.0 million, compared to $55.4 million in the second quarter of 2016.
Preliminary unaudited U.S. revenue for the second quarter of
2017 is expected to be in the range of $62.7
to $63.0 million. Preliminary unaudited international
revenue for the second quarter of 2017 is expected to be in the
range of $14.8 to $15.0 million.
The company expects worldwide revenue for the full year 2017 to
be in the range of $310.0 to $320.0
million.
Additionally, the company announced that Michael Enxing, Vice President of Sales, is no
longer with the company.
About Nevro
Headquartered in Redwood City, California, Nevro is a global
medical device company focused on providing innovative products
that improve the quality of life of patients suffering from
debilitating chronic pain. Nevro has developed and commercialized
the Senza® spinal cord stimulation system, an evidence-based
neuromodulation platform for the treatment of chronic pain. The
Senza system is the only SCS system that delivers Nevro's
proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are
trademarks of Nevro.
Forward-Looking Statements
In addition to
historical information, this press release contains forward-looking
statements with respect to our business, capital resources,
strategic initiatives and growth reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including continuing adoption of, and interest in, Senza in the
U.S. and international markets; and our expectations for worldwide
revenue for the full year of 2017. These forward-looking statements
are based upon information that is currently available to us or our
current expectations, speak only as of the date hereof, and are
subject to numerous risks and uncertainties, including our ability
to successfully commercialize our products; our ability to
manufacture our products to meet demand; the level and availability
of third-party payor reimbursement for our products; our ability to
effectively manage our anticipated growth; our ability to protect
our intellectual property rights and proprietary technologies; our
ability to operate our business without infringing the intellectual
property rights and proprietary technology of third parties;
competition in our industry; additional capital and credit
availability; our ability to attract and retain qualified
personnel; and product liability claims. These factors, together
with those that are described in greater detail in our Annual
Report on Form 10-K filed on February 23,
2017 and our Quarterly Report on Form 10-Q filed on
May 8, 2017, as well as any reports
that we may file with the Securities and Exchange Commission in the
future, may cause our actual results, performance or achievements
to differ materially and adversely from those anticipated or
implied by our forward-looking statements. We expressly disclaim
any obligation, except as required by law, or undertaking to update
or revise any such forward-looking statements. Our preliminary
operating results for the quarter ended June
30, 2017, are subject to adjustment as we complete our
year-end audit and other processes and are not necessarily
indicative of our operating results for any future periods.
Investor Relations Contact:
Nevro Investor
Relations
Katherine Bock
(650) 433-3247
ir@nevro.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nevro-announces-preliminary-unaudited-second-quarter-2017-revenue-and-business-update-300483284.html
SOURCE Nevro Corp.